![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif)
naloxone hydrochloride The hydrochloride salt of naloxone, a thebaine derivate with opioid antagonist activity. Naloxone binds to opioid receptors in the CNS in a competitve manner, reversing or inhibiting characteristic opioid effects, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence. This agent binds to mu-opioid receptors with a high affinity, and a lesser degree to kappa- and gamma-opioid receptors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) | Narcan | | ![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) | Abbreviation: | ![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) | NLX | | ![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115025237im_/http://www.cancer.gov/images/spacer.gif) |